Bristol Myers Squibb says AI now influences all its small-molecule drug designs and has helped improve manufacturing yields by up to 40% for certain medicines. The pharmaceutical company also says it has 25,000 AI agents in use across the business, offering a substantial, if company-reported, picture of AI moving into day-to-day operations.
Microsoft AI Watch analysis
What happened
The examples range from research and early development to manufacturing. BMS says AI influences the design of all its small-molecule medicines and most of its large-molecule medicines. In manufacturing, the company says optimised processes have improved yields by up to 40% for certain medicines.
BMS also describes RABIT, a custom agent built with Copilot Studio. It analyses meeting transcripts, identifies risks and action items, and delivers findings within Microsoft 365. A BMS director estimates that project managers using it save up to 20% of their time. The figures and examples come from a Microsoft customer story published on 5 October.
Why it matters
The account goes beyond the familiar office assistant: it describes AI being used in drug design and to get more doses from the same amount of manufacturing ingredients. If the reported results hold up, that makes AI relevant not just to administrative efficiency but to how medicines are developed and produced.
The numbers are company-reported, and the story does not provide independent evaluation or enough detail to compare the results across medicines. That matters, especially when a striking maximum can make a case study sound tidier than a complex operation usually is.
Our read
This is a useful window into how a large pharmaceutical company is putting AI to work across research, manufacturing and office tasks. The most consequential claims are also the ones that need more detail: how the yield improvement was measured, and what evidence supports the estimated time savings. Still, 25,000 agents is a deployment at a scale worth watching, not a speculative pilot with a name badge.
What to watch
- Whether BMS shares evaluation details for the reported yield improvements and time savings.
- How AI use in drug design changes as medicines progress through development.
- Whether BMS reports measurable outcomes from its 25,000 agents beyond adoption totals.
Discussion spark: For AI in drug development and manufacturing, should companies have to publish independently checked outcome data before presenting results such as yield improvements?
Sources and evidence
- Bristol Myers Squibb accelerates life-changing scientific pursuits with Microsoft AI – Microsoft (5 October 2026, 23:19 UTC)
not affiliated with or endorsed by Microsoft